1365-2125/asset/olbannerleft.gif?v=1&s=e86b92cac3efbbd2e255b9fa97ece9623eac0b54)
1365-2125/asset/olbannerright.gif?v=1&s=6a7c47d290382bf3bc40c62461bc36a371a081bf)
Pharmacokinetics and systemic endocrine effects of the phyto-oestrogen 8-prenylnaringenin after single oral doses to postmenopausal women
Article first published online: 21 APR 2006
DOI: 10.1111/j.1365-2125.2006.02656.x
Additional Information
How to Cite
Rad, M., Hümpel, M., Schaefer, O., Schoemaker, R. C., Schleuning, W.-D., Cohen, A. F. and Burggraaf, J. (2006), Pharmacokinetics and systemic endocrine effects of the phyto-oestrogen 8-prenylnaringenin after single oral doses to postmenopausal women. British Journal of Clinical Pharmacology, 62: 288–296. doi: 10.1111/j.1365-2125.2006.02656.x
Publication History
- Issue published online: 21 APR 2006
- Article first published online: 21 APR 2006
- Received 27 June 2005Accepted16 December 2005Published OnlineEarly21 April 2006
- Abstract
- Article
- References
- Cited By
Keywords:
- 8-PN;
- enterohepatic recirculation;
- HRT;
- LH;
- phyto-oestrogen
Aims
Pre-clinical data suggest that the racemic phyto-oestrogen 8-prenylnaringenin (8-PN) may have beneficial effects in postmenopausal women and may become an alternative to classical hormone replacement therapy (HRT) treatment regimes. The aim of this study was to investigate the pharmacokinetics, endocrine effects and tolerability of chemically synthesized 8-PN in postmenopausal women.
Methods
The study was performed using a randomized, double-blind, placebo-controlled, dose-escalation design with three groups of eight healthy postmenopausal women. In each group six subjects received 8-PN and two subjects placebo. 8-PN was given orally in doses of 50, 250 or 750 mg. Drug concentrations in serum, urine and faeces were measured up to 48 h and follicle-stimulating hormone/luteinizing hormone (LH) concentrations up to 24 h.
Results
All treatments were well tolerated and associated with a low incidence of (drug unrelated) adverse events. Serum concentrations of free 8-PN showed rapid drug absorption and secondary peaks suggestive of marked enterohepatic recirculation. Independent of the treatment group, approximately 30% of the dose was recovered in excreta as free compound or conjugates over the 48-h observation period. The first Cmax and AUC0−48 h showed dose linearity with ratios of 1 : 4.5 : 13.6 (Cmax) and 1 : 5.2 : 17.1 (AUC). The750- mg dose decreased LH concentrations by 16.7% (95% confidence interval 0.5, 30.2).
Conclusion
Single oral doses of up to 750 mg 8-PN were well tolerated by postmenopausal women. The pharmacokinetic profile of 8-PN was characterized by rapid and probably complete enteral absorption, high metabolic stability, pronounced enterohepatic recirculation and tight dose linearity. The decrease in LH serum concentrations found after the highest dose demonstrates the ability of 8-PN to exert systemic endocrine effects in postmenopausal women.